Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.
Video navigation menu
- 00 Change in regulatory obligations for CV safety new diabetes medications 01:
- Clinical outcomes studies with DPP4 inhibitors 02:45
- Trials with GLP-1 receptor agonists 03:38
- SGLT2-inhibitors - mechanism & trials 05:05
- Glycemic control algorithm 07:17
This video was recorded on October 27, 2017 in Boston and is a shortened version of the presentation that Dr. Wiviott gave there during the educational program 'Advances in Lipid Management and Cardiovascular Risk Reduction: New Horizons for 2018'
Dr. Stephen D. Wiviott is senior investigator and chairman of the Clinical Events Committee with the Thrombolysis in Myocardial Infarction (TIMI) Study Group. In addition, he is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and an associate professor of medicine at Harvard Medical School (HMS).
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.